




Instance: composition-en-13b9c5485a5dae25afc0e0c660688026
InstanceOf: CompositionUvEpi
Title: "Composition for tecovirimat Package Leaflet"
Description:  "Composition for tecovirimat Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpfc54850b1035986c41e71d72b4e83a0e)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - tecovirimat"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Tecovirimat SIGA is and what it is used for </li>
<li>What you need to know before you take Tecovirmat SIGA </li>
<li>How to take Tecovirimat SIGA </li>
<li>Possible side effects  </li>
<li>How to store Tecovirimat SIGA </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What tecovirimat is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What tecovirimat is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tecovirimat SIGA contains the active ingredient tecovirimat. </p>
<p>Tecovirimat SIGA is used to treat viral infections, such as smallpox, mpox and cowpox in adults and 
children weighing at least 13 kg. </p>
<p>Tecovirimat SIGA is also used to treat complications from smallpox vaccines. </p>
<p>Tecovirimat SIGA works by stopping the virus from spreading.  This will help your own body to build 
up protection against the virus until you are better. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take tecovirimat"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take tecovirimat"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Tecovirimat SIGA  </p>
<ul>
<li>if you are allergic to Tecovirimat SIGA or any of the other ingredients of this medicine (listed in 
section 6). </li>
</ul>
<p>Warnings and precautions  </p>
<p>Talk to your doctor or pharmacist before taking Tecovirimat SIGA. 
- if your immune system does not work properly (immunodeficiency) or you are taking medicines 
that weaken the immune system (such as high-dose corticosteroids, immunosuppresants or 
cancer medicines). 
- If you have reduced function of your liver or kidneys. </p>
<p>Children weighing less than 13 kg </p>
<p>This medicine should not be given to children who weigh less than 13 kg. </p>
<p>Other medicines and Tecovirimat SIGA </p>
<p>Tell your doctor if you are taking, have recently taken or might take any other medicines.<br />
You must tell your doctor if you are taking any of the following medicines:   </p>
<ul>
<li>repaglinide (a medicine used to treat blood sugar levels in diabetes)  </li>
<li>omeprazole, lansoprazole, or rabeprazole (used to treat ulcers or heart burn) </li>
<li>midazolam (a medicine used to put people to sleep before a surgical procedure) </li>
<li>bupropion (a medicine used to treat depression) </li>
<li>atorvastatin (a medicine use to treat high cholesterol) </li>
<li>flurbiprofen (a medicine used to treat pain) </li>
<li>methadone (a medicine used to treat pain or withdrawal symtoms of narcotics) </li>
<li>darunavir, maraviroc, or rilpivirine (used to treat HIV infection) </li>
<li>sildenafil, tadalafil, or vardenafil (used to treat erectile dysfunction) </li>
<li>voriconazole (a medicine used to treat fungus infections) </li>
<li>tacrolimus (a medicine used to suppress the immune system) </li>
</ul>
<p>Taking Tecovirimat SIGA with any of these may stop your medicines from working properly, or make 
any side effects worse.  Your doctor may need to give you a different medicine or adjust the dose of 
medicine you are taking.  The above is not a complete list of medicines that your doctor may need to 
alter. </p>
<p>Pregnancy and breast-feeding  </p>
<p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for 
advice before taking this medicine.  Tecovirimat SIGA is not recommended during pregnancy. </p>
<p>It is not known whether Tecovirmat SIGA is excreted in human milk.  Breast-feeding is not 
recommended during treatment with this medicine.  Tell your doctor if you are breast-feeding or are 
planning to breast-feed before taking this medicine. </p>
<p>Driving and using machines </p>
<p>Do not drive or operate machines if you feel dizzy. </p>
<p>Tecovirimat SIGA contains Lactose and sunset yellow (E110) </p>
<ul>
<li>Tecovirimat SIGA contains lactose.  If you have been told by your doctor that you have an 
intolerance to some sugars, contact your doctor before taking this medicine.  </li>
<li>This medicine also contains sunset yellow (E110), a colouring agent.  This may cause allergic 
reactions. </li>
</ul>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take tecovirimat"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take tecovirimat"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you.  Check with your doctor 
or pharmacist if you are not sure. </p>
<p>Adults and children weighing at least 13 kg </p>
<p>The recommended doses are described in the table below.  </p>
<p>Body Weight 
Dose 
13 kg to less than 25 kg 
One Tecovirimat SIGA 200 mg capsule every 12 hours for 14 days 
(200 mg two times a day) 
25 kg to less than 40 kg 
Two Tecovirimat SIGA 200 mg capsules every 12 hours for 14 days 
(400 mg two times a day) 
40 kg to less than 120 kg 
Three Tecovirimat SIGA 200 mg capsules every 12 hours for 14 days 
(600 mg two times a day) 
120 kg and above 
Three Tecovirimat SIGA 200 mg capsules every 8 hours for 14 days 
(600 mg three times a day) </p>
<p>Method of administration </p>
<p>Tecovirimat SIGA should be taken within 30 minutes of eating a meal of moderate calories and fat 
content. </p>
<p>Adults and children who have difficulty swallowing capsules </p>
<p>For patients who are not able to swallow the capsules, the doctor may recommend opening the hard 
capsule and mixing the contents with 30 mL of liquid (e.g., milk, chocolate milk) or soft food 
(e.g., apple sauce, yogurt).  </p>
<p>Wash and dry your hands before and after preparation.  Carefully open the capsule so that the contents 
do not spill or escape into the air.  Hold the capsule with the cap facing up and pull the cap away from 
the body of the capsule.  Use a small container for mixing.  Mix the entire contents of the capsule with 
30 mL of liquid (e.g. milk) or soft food (e.g. yogurt).  The mixture should be taken within 30 minutes 
after mixing and within 30 minutes of eating a meal. </p>
<p>The recommended paediatric and adult dosage and preparation instructions are given in the table 
below.  </p>
<p>Body 
weight 
Tecovirimat 
dose 
Amount of 
liquid or soft 
food 
Number of 
capsules 
Food and tecovirimat mixture 
instructions 
13 kg to less 
than 25 kg 
200 mg 
2 tablespoons 
1 Tecovirimat 
capsule 
Mix entire contents of 
1 Tecovirimat capsule with 
2 tablespoons of liquid or soft food. 
25 kg to less 
than 40 kg 
400 mg 
2 tablespoons 
2 Tecovirimat 
capsules 
Mix entire contents of 
2 Tecovirimat capsules with 
2 tablespoons of liquid or soft food. 
40 kg to less 
than 120 kg 
600 mg 
2 tablespoons 
3 Tecovirimat 
capsules 
Mix entire contents of 
3 Tecovirimat capsules with 
2 tablespoons of liquid or soft food. 
120 kg and 
above 
600 mg 
2 tablespoons 
3 Tecovirimat 
capsules 
Mix entire contents of 
3 Tecovirimat capsules with 
2 tablespoons of liquid or soft food. </p>
<p>If you take more Tecovirimat SIGA than you should </p>
<p>Let your doctor know if you take too many Tecovirimat SIGA capsules so that your doctor can 
monitor you for any signs or symptoms of side effects. </p>
<p>If you forget to take Tecovirimat SIGA  </p>
<p>If you miss a dose, skip that dose and continue with your next scheduled dose.  Do not take a double 
dose to make up for a forgotten dose. </p>
<p>If you stop taking Tecovirimat SIGA, your symptoms may return or become worse </p>
<p>Do not stop taking Tecovirimat SIGA before you have completed the course, or without talking to your 
doctor or pharmacist first. </p>
<p>If you vomit after taking Tecovirimat SIGA </p>
<p>If you vomit within 30 minutes of taking Tecovirimat SIGA, you may take another dose right away.<br />
If you vomit more than 30 minutes after taking Tecovirimat SIGA, do not take another dose and 
continue with your next scheduled dose. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>If you experience any of the following side effects, talk to your doctor or pharmacist.  This includes 
any possible side effects not listed in this leaflet. </p>
<p>Very common side effects (may affect more than 1 in 10 people) 
* Headache </p>
<p>Common side effects (may affect up to 1 in 10 people) 
* Dizziness 
* Feeling sick (nausea) or vomiting 
* Diarrhoea 
* Abdominal pain </p>
<p>Uncommon side effects (may affect up to 1 in 100 people) 
* Decreased appetite 
* Increased liver enzymes 
* Depression or anxiety 
* Irritability 
* Depression 
* Panic attacks 
* Migraine 
* Feeling tired or sleepy or unable to sleep 
* Being unable to concentrate or having a low attention span 
* Taste disturbances 
* Tingling or numbness in the hands, feet or or mouth 
* Mouth pain 
* Constipation 
* Flatulence 
* Indigestion or upset stomach 
* Abdominal discomfort or swelling 
* Dry mouth 
* Dry or chapped lips 
* Mouth ulcers 
* Belching or burping 
* Heartburn 
* Itching or rash (hives) 
* Joint pain and stiffness 
* Fever 
* Chills 
* Generally feeling unwell (malaise)<br />
<em> Pain 
* Feeling thirsty 
* If you have a scan of your brain s electrical activity called an electrocephalogram, it may show 
abnormal readings of electrical activity of the brain. <br />
</em> If you have a blood test, it may show that you have lower numbers of red blood cells or white 
blood cells or platelets than usual. 
* Increased heart rate (tachycardia) or irregular heart rate </p>
<p>Reporting of side effects </p>
<p>If you get any side effects, talk to your doctor or pharmacist.  This includes any possible side effects 
not listed in this leaflet.  You can also report side effects directly via the national reporting system 
listed in Appendix V.  By reporting side effects, you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store tecovirimat"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store tecovirimat"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the bottle after EXP.  The expiry date 
refers to the last day of that month. </p>
<p>Store in the original package in order to protect from light. </p>
<p>Store below 25 C. </p>
<p>Do not use this medicine if you notice that the capsule is broken or damaged in any way. </p>
<p>Do not throw away any medicines via wastewater or household waste.  Ask your pharmacist how to 
throw away medicines you no longer use.  These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Tecovirimat SIGA contains </p>
<ul>
<li>The active substance is tecovirimat monohydrate equivalent to 200 mg tecovirimat  </li>
<li>The other ingredients are: 
Capsule core:  Silica colloidal anhydrous, croscarmellose sodium (E468), hypromellose (E464), 
lactose monohydrate, magnesium stearate, cellulose, microcrystalline (E460) and sodium 
laurilsulfate (E487). 
Capsule shell:  gelatin, brilliant blue FCF (E133), erythrosine (E127), sunset yellow (E110) and 
titanium dioxide (E171). 
Printing ink:  shellac (E904), titanium dioxide (E171), isopropyl alcohol, ammonium hydroxide 
(E527), butyl alcohol, propylene glycol, and simeticone. </li>
</ul>
<p>What Tecovirimat SIGA looks like and contents of the pack </p>
<ul>
<li>Tecovirimat SIGA are orange and black capsules, each printed with  SIGA  and  ST-246  in 
white ink. The capsules are 21.7 millimeters long and 7.64 millimeters in diameter. </li>
<li>Tecovirimat SIGA is available in a pack containing 84 (2 bottles of 42) capsules. </li>
</ul>
<p>Marketing Authorisation Holder </p>
<p>SIGA Technologies Netherlands B.V. 
Prinsenhil 29, 
Breda 4825 AX, 
The Netherlands </p>
<p>Manufacturer </p>
<p>Millmount Healthcare Limited 
Block-7, City North Business Campus, 
Stamullen 
Co. Meath 
K32 YDIreland </p>
<p>This leaflet was last revised in  </p>
<p>This medicine has been authorised under  exceptional circumstances .  This means that for ethical 
reasons it has been impossible to get complete information on this medicine. 
The European Medicines Agency will review any new information on this medicine every year and 
this leaflet will be updated as necessary. </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site:  </p>         </div>"""      



Instance: composition-da-13b9c5485a5dae25afc0e0c660688026
InstanceOf: CompositionUvEpi
Title: "Composition for tecovirimat Package Leaflet"
Description:  "Composition for tecovirimat Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpfc54850b1035986c41e71d72b4e83a0e)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - tecovirimat"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Tecovirimat SIGA </li>
<li>Sådan skal du tage Tecovirimat SIGA </li>
<li>Bivirkninger  </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What tecovirimat is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What tecovirimat is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tecovirimat SIGA indeholder det aktive stof tecovirimat. </p>
<p>Tecovirimat SIGA bruges til behandling af virusinfektioner såsom kopper, mpox-sygdom og kokopper 
hos voksne og børn, der vejer mindst 13 kg. </p>
<p>Tecovirimat SIGA bruges også til behandling af komplikationer efter koppervacciner. </p>
<p>Tecovirimat SIGA virker ved at forhindre virussen i at sprede sig. Det vil hjælpe din egen krop med at 
danne beskyttelse mod virussen, indtil du har det bedre. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take tecovirimat"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take tecovirimat"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Tecovirimat SIGA  </p>
<ul>
<li>hvis du er allergisk over for tecovirimat eller et af de øvrige indholdsstoffer i Tecovirimat SIGA 
(angivet i punkt 6). </li>
</ul>
<p>Advarsler og forsigtighedsregler  </p>
<p>Kontakt lægen eller apotekspersonalet, før du tager Tecovirimat SIGA. 
- Hvis dit immunsystem ikke fungerer ordentligt (immundefekt), eller du tager medicin, som 
svækker immunsystemet (for eksempel høje doser kortikosteroider, immunundertrykkende 
lægemidler eller kræftmedicin). 
- Hvis du har nedsat lever- eller nyrefunktion. </p>
<p>Børn, der vejer under 13 kg </p>
<p>Dette lægemiddel bør ikke gives til børn, der vejer under 13 kg. </p>
<p>Brug af anden medicin sammen med Tecovirimat SIGA </p>
<p>Fortæl lægen, hvis du tager anden medicin, for nylig har taget anden medicin eller planlægger at tage 
anden medicin. Fortæl det til lægen, hvis du bruger et eller flere af nedenstående lægemidler: </p>
<ul>
<li>
<p>repaglinid (bruges til regulering af blodsukkerniveauerne, hvis man har diabetes)  </p>
</li>
<li>
<p>omeprazol, lansoprazol eller rabeprazol (bruges til behandling af mavesår eller halsbrand) </p>
</li>
<li>
<p>midazolam (bruges til bedøvelse inden en operation) </p>
</li>
<li>
<p>bupropion (bruges til behandling af depression) </p>
</li>
<li>
<p>atorvastatin (bruges til behandling af forhøjet kolesteroltal) </p>
</li>
<li>
<p>flurbiprofen (bruges til behandling af smerter) </p>
</li>
<li>
<p>methadon (bruges til behandling af smerter eller abstinenser efter narkotika) </p>
</li>
<li>
<p>darunavir, maraviroc eller rilpivirine (bruges til behandling af en hiv-infektion) </p>
</li>
<li>
<p>sildenafil, tadalafil eller vardenafil (bruges til behandling af erektil dysfunktion) </p>
</li>
<li>
<p>voriconazol (bruges til behandling af svampeinfektioner) </p>
</li>
<li>
<p>tacrolimus (bruges til undertrykkelse af immunsystemet) </p>
</li>
</ul>
<p>Brug af Tecovirimat SIGA sammen med et eller flere af ovenstående lægemidler kan medføre, at de 
ikke virker, som de skal, eller forværre eventuelle bivirkninger. Din læge vil muligvis skulle give dig 
et andet/andre lægemidler eller justere dosen af det/de lægemidler, du tager. Ovenstående er ikke en 
udtømmende liste over lægemidler, som din læge muligvis skal justere.  </p>
<p>Graviditet og amning  </p>
<p>Hvis du er gravid, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge 
din læge til råds, før du tager dette lægemiddel. Tecovirimat SIGA bør ikke anvendes under 
graviditeten. </p>
<p>Det er ukendt, om Tecovirmat SIGA udskilles i human mælk. Amning anbefales ikke under 
behandling med dette lægemiddel. Fortæl det til lægen, hvis du ammer eller planlægger at amme, før 
du tager dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed </p>
<p>Lad være med at føre motorkøretøj og betjene maskiner, hvis du føler dig svimmel. </p>
<p>Tecovirimat SIGA indeholder lactose og Sunset Yellow (E 110) </p>
<ul>
<li>
<p>Tecovirimat SIGA indeholder lactose. Kontakt lægen, før du tager dette lægemiddel, hvis lægen 
har fortalt dig, at du ikke tåler visse sukkerarter.  </p>
</li>
<li>
<p>Dette lægemiddel indeholder også farvestoffet Sunset Yellow (E 110). Det kan medføre 
allergiske reaktioner. </p>
</li>
</ul>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take tecovirimat"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take tecovirimat"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Voksne og børn, der vejer mindst 13 kg </p>
<p>De anbefalede doser er anført i nedenstående tabel.  </p>
<p>Legemsvægt 
Dosis 
13 kg til under 25 kg 
En Tecovirimat SIGA 200 mg kapsel hver 12. time i 14 dage 
(200 mg to gange dagligt) 
25 kg til under 40 kg 
To Tecovirimat SIGA 200 mg kapsler hver 12. time i 14 dage 
(400 mg to gange dagligt) 
40 kg til under 120 kg 
Tre Tecovirimat SIGA 200 mg kapsler hver 12. time i 14 dage<br />
(600 mg to gange dagligt) 
120 kg og derover 
Tre Tecovirimat SIGA 200 mg kapsler hver 8. time i 14 dage<br />
(600 mg tre gange dagligt) </p>
<p>Administration </p>
<p>Tecovirimat SIGA skal tages inden for 30 minutter efter et måltid med moderat indhold af kalorier og 
fedt. </p>
<p>Voksne og børn, som har svært ved at synke kapslerne </p>
<p>Til patienter, der ikke kan synke kapslerne, kan lægen anbefale, at den hårde kapsel åbnes, og 
indholdet blandes med 30 ml væske (fx mælk eller kakaomælk) eller blød mad (fx æblemos eller 
yoghurt).  </p>
<p>Vask og tør hænderne før og efter klargøring. Åbn kapslen forsigtigt, så indholdet ikke spildes eller 
strømmer ud i luften. Hold kapslen, så låget vender opad, og træk låget af modsat selve kapslen. Brug 
en lille beholder til opblanding. Bland hele kapslens indhold med 30 ml væske (fx mælk) eller blød 
mad (fx yoghurt). Blandingen skal tages inden for 30 minutter efter opblanding og inden for minutter efter et måltid.  </p>
<p>Nedenstående tabel viser den anbefalede dosering til børn og voksne samt instruktionerne til 
klargøring.  </p>
<p>Legemsvæg
t 
Tecovirimat-
dosis 
Mængde 
væske eller 
blød mad 
Antal kapsler 
Instruktioner til opblanding af 
mad og tecovirimat 
13 kg til 
under 25 kg 
200 mg 
2 
spiseskefulde 
1 Tecovirimat-
kapsel 
Bland hele indholdet af 1 
Tecovirimat-kapsel med 2 
spiseskefulde væske eller blød 
mad. 
25 kg til 
under 40 kg 
400 mg 
2 
spiseskefulde 
2 Tecovirimat-
kapsler 
Bland hele indholdet af 2 
Tecovirimat-kapsler med 2 
spiseskefulde væske eller blød 
mad. 
40 kg til 
under kg 
600 mg 
2 
spiseskefulde 
3 Tecovirimat-
kapsler 
Bland hele indholdet af 3 
Tecovirimat-kapsler med 2 
spiseskefulde væske eller blød 
mad. 
120 kg og 
derover 
600 mg 
2 
spiseskefulde 
3 Tecovirimat-
kapsler 
Bland hele indholdet af 3 
Tecovirimat-kapsler med 2 
spiseskefulde væske eller blød 
mad. </p>
<p>Hvis du har taget for meget Tecovirimat SIGA </p>
<p>Fortæl det til lægen, hvis du har taget for mange Tecovirimat SIGA-kapsler, så lægen kan holde øje 
med, om du får nogen tegn eller symptomer på bivirkninger. </p>
<p>Hvis du har glemt at tage Tecovirimat SIGA  </p>
<p>Hvis du har glemt en dosis, skal du springe den pågældende dosis over og fortsætte med din næste 
planlagte dosis. Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Hvis du holder op med at tage Tecovirimat SIGA, kan dine symptomer vende tilbage eller 
forværres </p>
<p>Du må ikke holde op med at tage Tecovirimat SIGA, før du har fuldført forløbet, eller du har talt med 
din læge eller apotekspersonalet. </p>
<p>Hvis du kaster op, efter du har taget Tecovirimat SIGA </p>
<p>Hvis du kaster op inden for 30 minutter, efter du har taget Tecovirimat SIGA, kan du tage en ny dosis 
med det samme. Hvis du kaster op mere end 30 minutter, efter du har taget Tecovirimat SIGA, må du 
ikke tage en ny dosis, men skal fortsætte med din næste planlagte dosis. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Hvis du får en eller flere af nedenstående bivirkninger, bør du tale med din læge eller 
apotekspersonalet. Dette gælder også mulige bivirkninger, som ikke er medtaget i denne 
indlægsseddel. </p>
<p>Meget almindelige bivirkninger (kan forekomme hos mere end 1 ud af 10 personer): </p>
<ul>
<li>Hovedpine </li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer): </p>
<ul>
<li>
<p>Svimmelhed </p>
</li>
<li>
<p>Kvalme eller opkastning </p>
</li>
<li>
<p>Diarré </p>
</li>
<li>
<p>Mavepine </p>
</li>
</ul>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 personer): </p>
<ul>
<li>
<p>Nedsat appetit </p>
</li>
<li>
<p>Forhøjede leverenzymer </p>
</li>
<li>
<p>Depression eller angst </p>
</li>
<li>
<p>Irritabilitet </p>
</li>
<li>
<p>Depression </p>
</li>
<li>
<p>Panikangst </p>
</li>
<li>
<p>Migræne </p>
</li>
<li>
<p>Træthed eller søvnighed eller søvnløshed </p>
</li>
<li>
<p>Koncentrationsbesvær eller nedsat opmærksomhed </p>
</li>
<li>
<p>Smagsforstyrrelser </p>
</li>
<li>
<p>Prikken eller følelsesløshed i hænder, fødder eller mund </p>
</li>
<li>
<p>Smerter i munden </p>
</li>
<li>
<p>Forstoppelse </p>
</li>
<li>
<p>Luft i maven </p>
</li>
<li>
<p>Fordøjelsesbesvær eller dårlig mave </p>
</li>
<li>
<p>Ubehag i maven eller mavegener </p>
</li>
<li>
<p>Mundtørhed </p>
</li>
<li>
<p>Tørre eller sprukne læber </p>
</li>
<li>
<p>Mundsår </p>
</li>
<li>
<p>Opstød eller ræben </p>
</li>
<li>
<p>Halsbrand </p>
</li>
<li>
<p>Kløe eller udslæt (nældefeber) </p>
</li>
<li>
<p>Ledsmerter og -stivhed </p>
</li>
<li>
<p>Feber </p>
</li>
<li>
<p>Kulderystelser </p>
</li>
<li>
<p>Generel utilpashed </p>
</li>
<li>
<p>Smerter </p>
</li>
<li>
<p>Tørst </p>
</li>
<li>
<p>Hvis du får lavet en scanning af din hjernes elektriske aktivitet, kaldet for et elektrocefalogram, 
kan det vise unormale målinger.   </p>
</li>
<li>
<p>Hvis du får taget en blodprøve, kan den vise, at du har et lavere antal røde blodlegemer, hvide 
blodlegemer eller blodplader end normalt. </p>
</li>
<li>
<p>Øget hjertefrekvens (takykardi) eller uregelmæssig hjerterytme </p>
</li>
</ul>
<p>Indberetning af bivirkninger </p>
<p>Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store tecovirimat"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store tecovirimat"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på flasken efter EXP. Udløbsdatoen er den sidste 
dag i den nævnte måned. </p>
<p>Opbevares i den originale pakning for at beskytte mod lys. </p>
<p>Opbevares ved temperaturer under 25 °C. </p>
<p>Brug ikke lægemidlet, hvis du bemærker, at kapslen er brudt eller ødelagt på den ene eller anden 
måde. </p>
<p>Af hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet eller skraldespanden. Spørg 
apotekspersonalet, hvordan du skal bortskaffe medicinrester.  </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tecovirimat SIGA indeholder:</p>
<ul>
<li>Aktive stof: tecovirimatmonohydrat svarende til 200 mg tecovirimat  </li>
<li>Øvrige indholdsstoffer: 
Kapselindhold: silica kolloid vandfri, croscarmellosenatrium (E 468), hypromellose (E 464), 
lactosemonohydrat, magnesiumstearat, mikrokrystallinsk cellulose (E 460) samt 
natriumlaurilsulfat (E 487). 
Kapselskal: gelatine, Brilliant Blue FCF (E 133), erythrosin (E 127), Sunset Yellow (E 110) 
samt titandioxid (E 171). 
Trykfarve: shellak (E 904), titandioxid (E 171), isopropylalkohol, ammoniumhydroxid (E 527), 
butylalkohol, propylenglykol samt simeticon. </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<ul>
<li>Tecovirimat SIGA er orange og sorte kapsler, hver påtrykt ‘SIGA®’ og ‘ST-246’ i hvid farve. 
Kapslerne er 21,7 millimeter lange og 7,64 millimeter i diameter. </li>
<li>Tecovirimat SIGA fås i en pakning med 84 (2 flasker à 42) kapsler. </li>
</ul>
<p>Indehaver af markedsføringstilladelsen . </p>
<p>SIGA Technologies Netherlands B.V. 
Prinsenhil 29, 
Breda 4825 AX, 
Holland </p>
<p>Fremstiller </p>
<p>Millmount Healthcare Limited 
Block-7, City North Business Campus, 
Stamullen 
Co. Meath 
K32 YDIrland </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Dette lægemiddel er godkendt under "særlige vilkår". Det betyder, at det af etiske grunde ikke har 
været muligt at opnå fuldstændig dokumentation for lægemidlet. 
Det Europæiske Lægemiddelagentur vil hvert år vurdere nye oplysninger om lægemidlet, og denne 
indlægsseddel vil om nødvendigt blive ajourført. </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-13b9c5485a5dae25afc0e0c660688026
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for tecovirimat Package Leaflet for language en"
Description: "ePI document Bundle for tecovirimat Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-13b9c5485a5dae25afc0e0c660688026"
* entry[0].resource = composition-en-13b9c5485a5dae25afc0e0c660688026

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp13b9c5485a5dae25afc0e0c660688026"
* entry[=].resource = mp13b9c5485a5dae25afc0e0c660688026
                            
                    
Instance: bundlepackageleaflet-da-13b9c5485a5dae25afc0e0c660688026
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for tecovirimat Package Leaflet for language da"
Description: "ePI document Bundle for tecovirimat Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-13b9c5485a5dae25afc0e0c660688026"
* entry[0].resource = composition-da-13b9c5485a5dae25afc0e0c660688026

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp13b9c5485a5dae25afc0e0c660688026"
* entry[=].resource = mp13b9c5485a5dae25afc0e0c660688026
                            
                    



Instance: mp13b9c5485a5dae25afc0e0c660688026
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product tecovirimat"
Description: "tecovirimat"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/21/1600/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "tecovirimat"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 13b9c5485a5dae25afc0e0c660688026ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "tecovirimat"

* status = #current
* mode = #working

* title = "List of all ePIs associated with tecovirimat"

* subject = Reference(mpfc54850b1035986c41e71d72b4e83a0e)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#tecovirimat "tecovirimat"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-13b9c5485a5dae25afc0e0c660688026) // tecovirimat en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-13b9c5485a5dae25afc0e0c660688026) // tecovirimat da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-13b9c5485a5dae25afc0e0c660688026
InstanceOf: List

* insert 13b9c5485a5dae25afc0e0c660688026ListRuleset
    